Brief: PhaseRx receives Orphan Drug Designation from FDA for PRX-ASL
20/09/2017 19:08
Sept 20 (Reuters) - PhaseRx Inc PZRX.O :
* PhaseRx receives Orphan Drug Designation from FDA for PRX-ASL for the
treatment of Argininosuccinate Lyase Deficiency
Source text for Eikon: ID:nPnyc6w5a
Further company coverage: PZRX.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on PZ Wind Down
See all newsBrief: Phaserx, Roivant Enter Into Asset Purchase Agreement
Brief: Phaserx Says Auction For Nearly All Of Co's Assets Was Held, But Did Not Conclude
Brief: Phaserx Revokes Proposed Distribution Record Date
Brief: PhaseRx Receives Decision From Nasdaq Hearings Panel For Continued Listing Of Shares
Brief: Phaserx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding